We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Placenta-Derived Decidua Stromal Cells for Hemorrhagic Cystitis after Stem Cell Transplantation.
- Authors
Aronsson-Kurttila, Wictor; Baygan, Arjang; Moretti, Gianluca; Remberger, Mats; Khoein, Bita; Moll, Guido; Sadeghi, Behnam; Ringdén, Olle
- Abstract
<bold><italic>Background/Aims:</italic></bold> Hemorrhagic cystitis (HC) is a serious complication after hematopoietic stem cell transplantation (HSCT). Stromal cells have been tested as therapy for HC. Decidua stromal cells (DSCs) protect the fetus from the mother's immune system. <bold><italic>Methods:</italic></bold> Eleven patients with HC of grades 3-4 were treated with DSCs after HSCT. The median age was 33 years (range 8-50), and the median dose of DSCs was 1.5 × 106/kg (range 0.7-2.5). The patients were given 1 dose (1-4). <bold><italic>Results:</italic></bold> In 5 patients, HC disappeared within 5 days after DSC infusion. Patients who received DSCs within 3 days after the start of HC had a duration of HC of 5 days and a shorter duration of pain than patients who were given DSCs later (<italic>p</italic> = 0.02). Three patients received DSCs prepared in albumin instead of AB-plasma and tended to have a shorter duration of pain (<italic>p</italic> = 0.07). There was no infusion toxicity. Adverse events were those often seen after HSCT. Nine of the 11 patients (82%) were alive 1 year after HSCT. <bold><italic>Conclusions:</italic></bold> Based on this pilot study, we started a randomized, placebo-controlled double-blind study using 2 doses of 1 × 106 DSCs/kg suspended in albumin for treatment of early HC.
- Subjects
STEM cell transplantation; STROMAL cells; CELL transplantation; CONNECTIVE tissue cells; MYELOSUPPRESSION
- Publication
Acta Haematologica, 2018, Vol 139, Issue 2, p106
- ISSN
0001-5792
- Publication type
Article
- DOI
10.1159/000485735